Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. High Reproducibility of ELISPOT Counts from Nine Different Laboratories

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

Diffuse gliomas are the most common primary malignant brain tumor. Although extracranial metastases are rarely observed, recent studies have shown the presence of circulating tumor cells (CTCs) in the blood of glioma patients, confirming that a subset of tumor cells are capable of entering the circulation. The isolation and characterization of CTCs could provide a non-invasive method for repeated analysis of the mutational and phenotypic state of the tumor during the course of disease. However, the efficient detection of glioma CTCs has proven to be challenging due to the lack of consistently expressed tumor markers and high inter- and intra-tumor heterogeneity. Thus, for this field to progress, an omnipresent but specific marker of glioma CTCs is required. In this article, we demonstrate how the recombinant malaria VAR2CSA protein (rVAR2) can be used for the capture and detection of glioma cell lines that are spiked into blood through binding to a cancer-specific oncofetal chondroitin sulfate (ofCS). When using rVAR2 pull-down from glioma cells, we identified a panel of proteoglycans, known to be essential for glioma progression. Finally, the clinical feasibility of this work is supported by the rVAR2-based isolation and detection of CTCs from glioma patient blood samples, which highlights ofCS as a potential clinical target for CTC isolation.

OriginalsprogEngelsk
TidsskriftCells
Vol/bind8
Udgave nummer9
Sider (fra-til)E998
ISSN2073-4409
DOI
StatusUdgivet - 28 aug. 2019

ID: 58970349